Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
results source : Www.alnylam.com save search
18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran Presented at SFNP
Published: 2022-01-21 (Crawled : 13:00) - alnylam.com
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: -10.41%
H: 0.0%
C: 0.0%
results phase 3
New Results from Phase 1 Study of Cemdisiran + Pozelimab Presented at ASH Annual Meeting 2021
Published: 2021-12-14 (Crawled : 03:00) - alnylam.com
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: 6.02%
H: 2.03%
C: -0.29%
phase 1 results phase 2 phase 3
New Long-Term Results for GIVLAARI® (givosiran) Presented at ASH Annual Meeting & Exposition
Published: 2021-12-13 (Crawled : 00:00) - alnylam.com
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: 6.02%
H: 2.03%
C: -0.29%
givlaari results
New Results from ATLAS Phase 3 Program with Fitusiran Presented at ASH Annual Meeting 2021
Published: 2021-12-12 (Crawled : 20:20) - alnylam.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 3.01%
H: 0.28%
C: -2.39%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.42%
H: 0.0%
C: 0.0%
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: 2.8%
H: 0.0%
C: 0.0%
results phase 3
ILLUMINATE-B Phase 3 Results of OXLUMO® (lumasiran) Published in Genetics in Medicine
Published: 2021-12-09 (Crawled : 15:30) - alnylam.com
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: 0.29%
H: 0.31%
C: -2.8%
oxlumo genetic results phase 3
New Results for Zilebesiran Presented at AHA Scientific Sessions 2021
Published: 2021-11-13 (Crawled : 16:20) - alnylam.com
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
| Email alert
Add to watchlist
results
Results from ILLUMINATE-C Phase 3 Study of Lumasiran Presented at ASN Kidney Week 2021
Published: 2021-11-05 (Crawled : 18:00) - alnylam.com
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: 0.0%
results phase 3 kidney
New Long-Term Results for GIVLAARI® (givosiran) Presented at UEG Week Virtual 2021
Published: 2021-10-04 (Crawled : 13:00) - alnylam.com
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: 3.34%
H: 1.56%
C: 0.01%
results
New Results from the OXLUMO® (lumasiran) Clinical Program Presented at AUA Annual Meeting
Published: 2021-09-10 (Crawled : 18:00) - alnylam.com
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: 0.43%
H: 1.06%
C: -0.46%
results
New Results for Vutrisiran at EU-ATTR Amyloidosis Meeting
Published: 2021-09-07 (Crawled : 14:00) - alnylam.com
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: -0.93%
H: 0.0%
C: -4.76%
results
Complete Results from Phase 1/2 Study of Lumasiran (OXLUMO®) Published in Clinical Journal of the American Society of Nephrology
Published: 2021-05-15 (Crawled : 04:20) - alnylam.com
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
| Email alert
Add to watchlist
phase 1 results phase 3 phase 2
Early Results on Clinical Outcome Measures Presented for OXLUMO® (lumasiran) at ASPN/PAS 2021 Annual Congress
Published: 2021-05-03 (Crawled : 12:00) - alnylam.com
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: -0.11%
H: 0.09%
C: -3.66%
tcom results
HELIOS-A Phase 3 Results for Vutrisiran Presented at AAN
Published: 2021-04-19 (Crawled : 19:00) - alnylam.com
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: -4.11%
H: 3.92%
C: 3.25%
results phase 3 presentation
New Results for ALN-AGT at the ESH-ISH 2021 Joint Meeting
Published: 2021-04-11 (Crawled : 16:20) - alnylam.com
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
| Email alert
Add to watchlist
results
New Analyses of OXLUMO® (lumasiran) ILLUMINATE-A Results at the National Kidney Foundation Virtual Spring Clinical Meetings
Published: 2021-04-10 (Crawled : 20:20) - alnylam.com
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
| Email alert
Add to watchlist
results kidney
ILLUMINATE-A Phase 3 Results for Lumasiran Published in The New England Journal of Medicine
Published: 2021-03-31 (Crawled : 22:00) - alnylam.com
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: 1.4%
H: 1.39%
C: -0.95%
results phase 3
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.